Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes

被引:29
|
作者
Engelen, Suzanne E. [1 ]
van der Graaf, Yolanda [5 ]
Stam-Slob, Manon C. [1 ]
Grobbee, Diederick E. [5 ]
Cramer, Maarten J. [2 ]
Kappelle, L. Jaap [3 ]
de Borst, Gert J. [4 ]
Visseren, Frank L. J. [1 ]
Westerink, Jan [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Cardiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands
[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
关键词
Type; 2; diabetes; Cardiovascular disease; Interventions; PERIPHERAL ARTERIAL-DISEASE; SIROLIMUS-ELUTING STENTS; OUTCOMES; THROMBOSIS; MELLITUS; RISK; MORTALITY;
D O I
10.1016/j.ijcard.2017.07.081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Diabetes mellitus is associated with an increased risk for cardiovascular morbidity and mortality. The vascular burden in terms of incidence of cardiovascular events (CVE) and vascular interventions is however poorly quantified. In this study we evaluated the incidence rates of CVE and vascular interventions in patients with type 2 diabetes (T2DM) with and without cardiovascular disease (CVD) in comparison to patients without type 2 diabetes. Research design and methods: In a cohort of 9.808 high-risk patients with and without cardiovascular disease and type 2 diabetes originated from the ongoing, single-center prospective SMART (Second Manifestations of ARTerial disease) cohort, the number and incidence rates of CVE and interventions were calculated. The incidence rates were adjusted for confounders using Poisson regression models. CVE were defined as vascular death, stroke and myocardial infarction (MI). Interventions were defined as percutaneous coronary intervention, coronary artery bypass grafting, percutaneous transluminal angioplasty or stenting of the peripheral arteries and amputation. Results: Patients with T2DM and CVD had a 4-fold higher incidence rate of CVE and a 8-fold higher incidence rate of vascular interventions compared to high-risk patients without T2DM and CVD after adjusting for confounders. The incidence rate for the composite of non-fatal MI, non-fatal stroke and vascular death was 5.8 per 1000 person-years in patients without T2DM or CVD at baseline, 15.2 per 1000 person-years in patients with T2DM but without CVD at baseline, 26.0 per 1000 person-years in patients without T2DM but with CVD and 40.7 per 1000 person-years in patients with both T2DM and CVD at baseline. A similar increasing incidence rate was seen for all vascular interventions from patients without T2DM or CVD to patients with both T2DM and CVD. Conclusions: Patients with type 2 diabetes or CVD are subject to an increased incidence of cardiovascular events and interventions compared to high-risk patients without type 2 diabetes or vascular disease. Patients with type 2 diabetes and CVD have the highest incidence of new cardiovascular diseases and vascular interventions when compared to patients without type 2 diabetes and CVD. These results underline the need for optimal risk factor treatment as well as the need for new prevention and treatment strategies in this very high risk population. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [31] Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events
    Saely, Christoph H.
    Rein, Philipp
    Vonbank, Alexander
    Huber, Kurt
    Drexel, Heinz
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (03) : 776 - 780
  • [32] Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations
    Coutinho, Anna D.
    Raju, Aditya D.
    Wang, Weijia
    Stafkey-Mailey, Dana
    Shetty, Sharash
    Sander, Stephen D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 1005 - 1012
  • [33] Cardio Vascular Autonomic Dysfunction in Type 2 Diabetes Patients with Microalbuminuria
    Samin, Kashif Ali
    Gardazi, Aamena
    Alina, Humal
    Malik, Sara
    Fayyaz, Muhammad Najam Ul Saqib
    Rasheeq, Talha
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (05): : 1162 - 1164
  • [34] The value of ankle-branchial index screening for cardiovascular disease in type 2 diabetes
    Xu, Lei
    He, Rui
    Hua, Xiaohan
    Zhao, Jun
    Zhao, Jungong
    Zeng, Hui
    Li, Lianxi
    Liu, Fang
    Jia, Weiping
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (01)
  • [35] Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
    Filippatos, Gerasimos
    Anker, Stefan D.
    Pitt, Bertram
    McGuire, Darren K.
    Rossing, Peter
    Ruilope, Luis M.
    Butler, Javed
    Jankowska, Ewa A.
    Michos, Erin D.
    Farmakis, Dimitrios
    Farjat, Alfredo E.
    Kolkhof, Peter
    Scalise, Andrea
    Joseph, Amer
    Bakris, George L.
    Agarwal, Rajiv
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 9 (01) : 85 - 93
  • [36] Trajectories of anxiety symptoms and associations with incident cardiovascular disease in adults with type 2 diabetes
    Deschenes, Sonya S.
    Burns, Rachel J.
    Schmitz, Norbert
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2018, 104 : 95 - 100
  • [37] Canagliflozin and cardiovascular and renal events in type 2 diabetes
    Guthrie, Robert
    POSTGRADUATE MEDICINE, 2018, 130 (02) : 149 - 153
  • [38] Vascular Age as a Cardiovascular Risk Marker in Asymptomatic Patients with Type 2 Diabetes
    Sousa Vergara Palma, Catia Cristina Silva
    Lopes, Pablo Moura
    Clemente Silva, Eliete Leao
    da Matta Bevilaqua, Maria de Fatima
    Bomfim, Alfredo de Souza
    Gomes, Marilia Brito
    DIABETES METABOLIC SYNDROME AND OBESITY, 2020, 13 : 2505 - 2514
  • [39] Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project
    Ohmura, Hirotoshi
    Mita, Tomoya
    Matsuoka, Joe
    Nojiri, Shuko
    Nishizaki, Yuji
    Watada, Hirotaka
    Daida, Hiroyuki
    DIABETES THERAPY, 2019, 10 (03) : 1099 - 1111
  • [40] The effect of guideline revisions on vascular complications of type 2 diabetes
    Heijmans, Ralph
    Singh, Sunny S.
    Lieverse, Aloysius G.
    Sijbrands, Eric J. G.
    van Hoek, Mandy
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10